Back to Journals » Open Access Rheumatology: Research and Reviews » Volume 8

Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series

Authors Brown AN

Received 21 May 2016

Accepted for publication 9 September 2016

Published 11 November 2016 Volume 2016:8 Pages 97—102

DOI https://doi.org/10.2147/OARRR.S113288

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Professor Chuan-Ju Liu


Alan N Brown

Low Country Rheumatology, North Charleston, SC, USA

Purpose: Although numerous treatment options are available for patients with psoriatic arthritis (PsA), a need for effective and tolerable treatments remains for patients with refractory disease who have failed previous therapies and continue to experience tender and/or swollen joints, pain, and disease activity. Repository corticotropin injection (RCI) is believed to produce steroidogenic, steroid-independent, anti-inflammatory, and immunomodulatory effects in patients with rheumatic disorders, such as PsA. Limited literature exists on the use of RCI in patients with refractory PsA. The objective of this case series is to provide information on the clinical features of patients with refractory PsA and their response to RCI.
Patients: Nine patients treated with RCI for refractory PsA were retrospectively identified and included in the case series.
Results: All the nine patients experienced at least transient improvements in their active skin and joint disease. In some patients, it was necessary to titrate the RCI to an appropriate dose. RCI was used in some patients to bridge with another PsA therapy, such as apremilast or certolizumab. RCI was well tolerated, but discontinued in three patients due to preexisting conditions (hypertension and hyperglycemia).
Conclusion: RCI may be a safe and effective option for patients with refractory PsA who failed therapy with multiple previous treatments.

Keywords: treatment, adrenocorticotropic hormone, psoriatic arthritis biologic failures, ­melanocortin, refractory

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]